HMR 1556
Based on 2 publication(s) in Google Scholar
HMR 1556, a chromanol derivative, is a potent IKs blocker with IC50s of 10.5 nM and 34 nM in canine and guinea pig left ventricular myocytes, respectively.
For research use only. We do not sell to patients.
- Purity: 99.95%
- CAS No.: 223749-46-0
- Formula: C17H24F3NO5S
- Molecular Weight:411.44
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
Publications Citing Use of MedChemExpress (MCE) HMR 1556
More
Biological Activity
IC50: 10.5 nM (IKs in canine left ventricular myocytes), 34 nM (IKs in guinea pig left ventricular myocytes)[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Oocyte | IC50 |
0.12 μM
Compound: 10a
|
Inhibition of human IKs-channel expressed in Xenopus oocytes
Inhibition of human IKs-channel expressed in Xenopus oocytes
|
[PMID: 11689069] |
| Oocyte | IC50 |
120 nM
Compound: 22 HMR-1556
|
Inhibition of guinea pig Iks potassium channel expressed in Xenopus oocytes
Inhibition of guinea pig Iks potassium channel expressed in Xenopus oocytes
|
[PMID: 14998318] |
| Oocyte | IC50 |
120 nM
Compound: 51 (HMR-1556)
|
Inhibition of IKs currents in Xenopus oocytes
Inhibition of IKs currents in Xenopus oocytes
|
[PMID: 11356099] |
Chemical Information
-
CAS No. 223749-46-0
-
Appearance Solid
-
Molecular Weight 411.44
-
Formula C17H24F3NO5S
-
Color White to off-white
-
SMILES
CS(N([C@H]1C2=CC(OCCCC(F)(F)F)=CC=C2OC(C)(C)[C@@H]1O)C)(=O)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Br J Pharmacol
2025 Aug 20. PMID: 40831387 -
Channels
A conserved arginine/lysine-based motif promotes ER export of KCNE1 and KCNE2 to regulate KCNQ1 channel activity. [Abstract]2019 Dec;13(1):483-497. PMID: 31679457
Solvent & Solubility
DMSO : 100 mg/mL (243.05 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.5 mg/mL (6.08 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (6.08 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (274 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Thomas GP, et al. HMR 1556, a potent and selective blocker of slowly activating delayed rectifier potassium current. J Cardiovasc Pharmacol. 2003 Jan;41(1):140-7. [Content Brief]
[2]. Gerlach U,et al. Synthesis and activity of novel and selective I(Ks)-channel blockers. J Med Chem. 2001 Nov 8;44(23):3831-7. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.4305 mL | 12.1524 mL | 24.3049 mL | 60.7622 mL |
| 5 mM | 0.4861 mL | 2.4305 mL | 4.8610 mL | 12.1524 mL | |
| 10 mM | 0.2430 mL | 1.2152 mL | 2.4305 mL | 6.0762 mL | |
| 15 mM | 0.1620 mL | 0.8102 mL | 1.6203 mL | 4.0508 mL | |
| 20 mM | 0.1215 mL | 0.6076 mL | 1.2152 mL | 3.0381 mL | |
| 25 mM | 0.0972 mL | 0.4861 mL | 0.9722 mL | 2.4305 mL | |
| 30 mM | 0.0810 mL | 0.4051 mL | 0.8102 mL | 2.0254 mL | |
| 40 mM | 0.0608 mL | 0.3038 mL | 0.6076 mL | 1.5191 mL | |
| 50 mM | 0.0486 mL | 0.2430 mL | 0.4861 mL | 1.2152 mL | |
| 60 mM | 0.0405 mL | 0.2025 mL | 0.4051 mL | 1.0127 mL | |
| 80 mM | 0.0304 mL | 0.1519 mL | 0.3038 mL | 0.7595 mL | |
| 100 mM | 0.0243 mL | 0.1215 mL | 0.2430 mL | 0.6076 mL |